Quality of life in patients with advanced non-small cell lung cancer

Cancer Nursing

Volumn 29, Issue 2, 2006, Pages 104-110

  Bozcuk, Hakan ^a   Dalmis, Berna ^a   Samur, Mustafa ^a   Ozdogan, Mustafa ^a   Artac, Mehmet ^a   Savas, Burhan ^a  

^a AKDENIZ UNIVERSITY   (Turkey)

Author keywords

Chemotherapy; Non small cell lung cancer; Quality of life

Indexed keywords

DOCETAXEL; ETOPOSIDE; GEMCITABINE; NAVELBINE; PACLITAXEL; PLATINUM; ANTINEOPLASTIC AGENT;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER PATIENT; CLINICAL ARTICLE; FATIGUE; FEMALE; HUMAN; LUNG NON SMALL CELL CANCER; MALE; PERFORMANCE; PHYSICAL CAPACITY; PRIORITY JOURNAL; QUALITY OF LIFE; QUESTIONNAIRE; AGE; HEALTH STATUS; LUNG TUMOR; MIDDLE AGED; MULTIVARIATE ANALYSIS; STATISTICAL MODEL;

ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; FEMALE; HEALTH STATUS; HUMANS; LINEAR MODELS; LUNG NEOPLASMS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; QUALITY OF LIFE;

EID: 33646686375     PISSN: 0162220X     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002820-200603000-00004     Document Type: Article

References (22)

1. Smit EF, vanMeerbeeck JP, Lianes P, et al. European Organization for Research and Treatment of Cancer Lung Cancer Group. Three-arm randomized study of two cisplatin-based regimens and paclitaxel plus gemcitabine in advanced non-small-cell lung cancer: a phase III trial of the European Organization for Research and Treatment of Cancer Lung Cancer Group-EORTC 08975. J Clin Oncol. 2003;21(21):3909-3917.
2. Fossella F, Pereira JR, von Pawel J, et al. Randomized, multinational, phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for advanced non-small-cell lung cancer: the TAX 326 study group. J Clin Oncol. 2003;21(16):3016-3024.
3. Thongprasert S, Sanguanmitra P, Juthapan W, Clinch J. Relationship between quality of life and clinical outcomes in advanced non-small cell lung cancer: best supportive care (BSC) versus BSC plus chemotherapy. Lung Cancer. 1999;24(1):17-24.
4. Hensing TA, Peterman AH, Schell MJ, Lee JH, Socinski MA. The impact of age on toxicity, response rate, quality of life, and survival in patients with advanced, Stage IIIB or IV nonsmall cell lung carcinoma treated with carboplatin and paclitaxel. Cancer. 2003;98(4):779-788.
5. Vansteenkiste J, Vandebroek J, Nackaerts K, et al. Influence of cisplatin-use, age, performance status and duration of chemotherapy on symptom control in advanced non-small cell lung cancer: detailed symptom analysis of a randomised study comparing cisplatin-vindesine to gemcitabine. Lung Cancer. 2003;40(2):191-199.
6. Morita S, Kobayashi K, Eguchi K, et al. Influence of clinical parameters on quality of life during chemotherapy in patients with advanced non-small cell lung cancer: application of a general linear model. Jpn J Clin Oncol. 2003;33(9):470-476.
7. Montazeri A, Milroy R, Hole D, McEwen J, Gillis CR. Quality of life in lung cancer patients as an important prognostic factor. Lung Cancer. 2001;31:233-240.
8. Hollen PJ, Gralla RJ, Cox C, Eberly SW, Kris MG. A dilemma in analysis: issues in the serial measurement of quality of life in patients with advanced lung cancer. Lung Cancer. 1997;18(2):119-136.
9. Aaranson NK, Ahmedzai S, Bergman B, et al. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst. 1993;85(5):365-376.
10. Bergman B, Aaranson NK, Ahmedzai S, Kaasa S, Sullivan M. The EORTC QLQ-LC13: a modular supplement to the EORTC Core Quality of Life Questionnaire (QLQ-C30) for use in lung cancer clinical trials. EORTC Study Group on Quality of Life. Eur J Cancer. 1994;30A(5):635-642.
11. Hollen PJ, Gralla RJ, Kris MG, Cox C. Quality of life assessment in individuals with lung cancer: testing the Lung Cancer Symptom Scale (LCSS). Eur J Cancer. 1993;29A(suppl 1):S51-S58.
12. Cella DF, Bonomi AE, Lloyd SR, Tulsky DS, Kaplan E, Bonomi P. Reliability and validity of the Functional Assessment of Cancer Therapy - Lung (FACT-L) quality of life instrument. Lung Cancer. 1995;12(3):199-220.
13. Hollen PJ, Gralla RJ. Comparison of instruments for measuring quality of life in patients with lung cancer. Semin Oncol. 1996;23(2 suppl 5):31-40.
14. Watanabe H, Yamamoto S, Kunitoh H, et al. Tumor response to chemotherapy: the validity and reproducibility of RECIST guidelines in NSCLC patients. Cancer Sci. 2003;94(11):1015-1020.
15. Fayers P, Aaranson N, Bjordal K, Sullivan M. EORTC QLQ-C30 Scoring Manual. Brussels, Belgium: European Organization for Research and Treatment of Cancer.
16. Osoba D, Rodrigues G, Myles J, Zee B, Pater J. Interpreting the significance of changes in health-related quality-of-life scores. J Clin Oncol. 1998;16(1):139-144.
17. Gridelli C, Gallo C, Shepherd FA, et al. Gemcitabine plus vinorelbine compared with cisplatin plus vinorelbine or cisplatin plus gemcitabine for advanced non-small-cell lung cancer: a phase III trial of the Italian GEMVIN Investigators and the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol. 2003;21(16):3025-3034.
18. Bozcuk H, Martin C. Does treatment delay affect survival in non-small cell lung cancer? A retrospective analysis from a single UK centre. Lung Cancer. 2001;34(2):243-252.
19. Langendijk H, Aaronson NK, de Jong JM, ten Velde GP, Muller MJ, Wouters M. The prognostic impact of quality of life assessed with the EORTC QLQ-C30 in inoperable non-small cell lung carcinoma treated with radiotherapy. Radiother Oncol. April 2000;55(1):19-25.
20. Kaasa S, Mastekaasa A, Lund E. Prognostic factors for patients with inoperable non-small cell lung cancer, limited disease. The importance of patients' subjective experience of disease and psychosocial well-being. Radiother Oncol. 1989;15(3):235-242.
21. Ten Bokkel Huinink WW, Bergman B, Chemaissani A, et al. Single-agent gemcitabine: an active and better tolerated alternative to standard cisplatin-based chemotherapy in locally advanced or metastatic non-small cell lung cancer. Lung Cancer. 1999;26(2):85-94.
22. Kelly K. The benefits of achieving stable disease in advanced lung cancer. Oncology (Williston Park). 2003;17(7):957-963.